Valproate sodium contraindications: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Valproate sodium}} {{CMG}} ==Title== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPACON (VALPROATE SODIUM) INJECTION [ABBVIE IN..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
Depacon should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPACON (VALPROATE SODIUM) INJECTION [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da030cbb-40f6-4805-9883-0d8945afbcc3#section-1 | publisher = | date = | accessdate = }}</ref> | Depacon is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. | ||
Depacon is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)]. | |||
Depacon is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPACON (VALPROATE SODIUM) INJECTION [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da030cbb-40f6-4805-9883-0d8945afbcc3#section-1 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 20:25, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Depacon should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].
Depacon is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].
Depacon is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].
Depacon is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].[1]
References
Adapted from the FDA Package Insert.